Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
Rheumatoid Arthritis – Current Treatment – Current Treatment: Physician Insights – Rheumatoid Arthritis (EU5)
Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-…
Metabolic Dysfunction-Associated Steatohepatitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…
Narcolepsy – Unmet Need – Unmet Need – Narcolepsy with or without cataplexy (US/EU)
Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…
Systemic Lupus Erythematosus – Current Treatment – Current Treatment: Physician Insights – Systemic Lupus Erythematosus (EU5)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations…
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…
